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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which attacks the
motor system. There is a family history in approximately 10% percent of cases and 20% of such
families have point mutations in the Cu, Zn superoxide dimutase 1 (SOD1) gene. Pre-symp‐
tomatic loss of motor neurons has been identified prior to the onset of symptoms in SOD1
mice. This loss was biphasic with initial loss in the pre-symptomatic phase followed by a period
of stabilisation and then gradual loss at time of weakness to death. (Kong & Xu, 1998).
In order to determine the time course of motor neurone loss prior to symptomatic onset of
disease, a longitudinal study of at-risk asymptomatic individuals (i.e. SOD1 mutation carriers
with no neurological symptoms or signs as determined by a neurologist) was performed. There
was no detectable difference in the number of motor units in SOD1 mutation carriers compared
to their SOD1 negative family controls. (Aggarwal & Nicholson, 2001). This may indicate that
mutation carriers have undetectable loss of motor neurones until rapid and widespread cell
death of motor neurones occurs, coinciding with the onset of symptomatic features. This
implies that the disease is not the end result of the slow attrition of motor neurones. (Aggarwal,
2009).
This longitudinal study was extended on 20 asymptomatic carriers of the Cu, Zn superoxide
dimutase 1 (SOD1) point mutation. There was a sudden reduction in MUNE, several months
prior to the onset of weakness. (Aggarwal & Nicholson 2002) and (Aggarwal, 2009). This
suggests that gradual pre-clinical loss of motor neurones does not occur in asymptomatic SOD1
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mutation carriers and supports the observation that sudden, catastrophic loss of motor
neurones occurs immediately prior to the onset of symptoms and the development of the
disease, rather than a gradual attrition of motor neurones over time. These results suggest that
there may be a biological trigger initiating rapid cell loss, just prior to the onset of symptoms.
Current treatment for sporadic ALS or Cu, Zn superoxide dimutase 1 (SOD 1 mutation) familial
ALS, produces only a modest increase in survival. The excitatory amino acid neurotransmitter,
glutamate, may be involved in the pathogenesis of ALS. Riluzole, an anti-glutamate agent,
remains the only disease modifying therapy available for ALS and has been used since 1995.
(Cheah et al, 2010). Treatment of human ALS patients or transgenic Cu, Zn superoxide
dimutase 1 (SOD 1) mice, most commonly produce a modest but significant increase in
survival. (Bensimon et al, 1994). It has also been shown to have a small beneficial effect on
bulbar function, but not muscle strength.
Using the statistical motor unit number estimation (MUNE) technique, (Daube, 1995), a
longitudinal study was performed to determine whether early institution of Riluzole can
reduce that rate of motor unit loss in familial amyotrophic lateral sclerosis (fALS). Motor unit
numbers were estimated from the right abductor pollicis brevis (APB) and right extensor
digitorum brevis (EDB) muscles. Our subjects had a presumptive diagnosis of fALS, as
electromyography (EMG) was “normal” with an absence of fasciculation and fibrillation
potentials, normal motor unit potentials and normal recruitment. MUNE is more sensitive that
EMG and once changes occur on conventional EMG studies, the window of opportunity to
influence the progression of this condition has been missed. They were all commenced on
Riluzole therapy in the pre-symptomatic phase, as soon as loss of motor units was detected
using motor unit number estimation (MUNE). After commencing Riluzole, “symptomatic”
improvement occurred, especially a decrease in muscle fasciculations and an improvement in
MUNE. Riluzole is not a disease altering agent but possibly if given early in the pre-sympto‐
matic phase of the disease, before significant motor neurone loss has occurred, it may have
some therapeutic benefit.
This effect may have implications for the management of asymptomatic carriers of the SOD 1
gene, as these subjects are at risk of developing ALS.
Regular follow-up of SOD1 carriers with MUNE may lead to early diagnosis, creating an
opportunity for future approaches and therapies aimed at preserving motor neurones rather
than replacing lost motor neurones. Detecting the onset of motor neurone loss in asymptomatic
individuals will identify those who may benefit from early institution of an active management
program to improve their quality of life, until more effective treatment modalities are available
for this devastating condition.
2. Background
Amyotrophic lateral sclerosis (ALS) is a group of fatal, neurodegenerative disorders, which is
characterised pathologically by progressive degeneration and loss of motor neurones in the
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anterior horn cells of the spinal cord, motor nuclei of the brainstem and the descending
pathways within the corticospinal tracts. The term amyotrophic lateral sclerosis (ALS) is used
synonymously with motor neurone disease (MND) in the USA, but in the UK and Australia
is used only to refer to patients who have a combination of upper and lower motor neurone
dysfunction. (Talbot, 2002).
It is primarily a condition of middle to late life, with onset of symptoms between the ages of
50 and 70 and a mean age of onset of 57.4 years. (Ringel et al., 1993). Occasionally, it arises as
early as the 2nd decade or as late as the 9th decade. In a natural history study, the overall median
survival is 4.0 years from the onset of symptoms, but only 2.1 years from the time of diagnosis.
(Ringel et al., 1993). In a study performed at the Mayo clinic, approximately 50% of patients
died within 3 years of referral, but 20% were still alive at 5 years and 10% were still alive at 10
years. (Mulder & Howard, 1976).
Aging, motor neurone diseases and many peripheral neuropathies are all associated with loss
of motor neurones or axons. When the disorders are recent or rapidly progressive, the extent
of the loss may be indicated by weakness and wasting. In slowly progressive denervating
conditions, like MND, loss of more than 50-80% of motor units may occur with little or no
clinically apparent weakness.
It has been showed that patients with substantial chronic denervation could maintain normal
muscle twitch tension until loss of about 70-80% of motor units occurred. (McComas, 1971).
The surviving motor neurones enlarge their territories, through collateral sprouting (reinner‐
vation) to keep pace with cell loss, to maintain the muscle maximum compound muscle action
potential (CMAP), until late in the disease. At this point, collateral reinnervation is no longer
able to provide full functional compensation. (Campbell et al., 1973).
In MND, needle electromyography often reveals evidence of chronic reinnervation (increased
motor unit action potential amplitudes and duration with reduced recruitment), but provides
little direct evidence to the extent of motor neurone and axonal loss. The supramaximal CMAP
amplitude also provides little direct evidence of the extent of motor neurone loss. Normal
CMAP amplitudes might mistakenly suggest that motor neurone loss has not occurred yet.
(Shefner, 2001).
Motor unit number estimation (MUNE) is a more reliable method for following changes in
neurogenic disorders than the CMAP amplitude. It estimates the number of functioning lower
motor neurones innervating a muscle or a group of muscles i.e. the number of motor units,
which can be excited by electrical stimulation. It is therefore an indirect measure of motor
neurone loss, rather than a measure of primary pathology. It can identify that the number of
motor units may be well below normal, in the presence of normal CMAP amplitudes. (Brown,
1972).
Pre-symptomatic loss of motor neurones has been identified in an animal model of the disease
(transgenic mice expressing mutant human SOD1-G93A). The initial loss in the pre-sympto‐
matic phase related to severe motor axonal degeneration due to vacuolar changes in motor
neurones and a slow decrease in CMAP amplitudes. After a period of stabilisation, there was
a gradual loss of motor neurones and a rapid decrease in CMAP amplitude, at the onset of
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weakness due to myelin alteration. At this point, there was a striking loss of motor units. There
was also decrease in evoked motor potentials (an indirect measure of the number of motor
units), prior to the onset of symptoms. The onset of disease in transgenic G93A mice involves
a sharp decline of muscle strength and a transient explosive increase in vacuoles derived from
degenerating mitochondria, but little motor neurone death. These did not die until the terminal
stage. (Kong & Xu, 1998). The decline exhibited kinetics consistent with both a constant and
exponentially decreasing risk of neuronal death. An escalating risk forced by cumulative
damage was not responsible for cell death. (Azzouz et al., 1997).
It is possible that the high metabolic activity in motor neurones, combined with the toxic
oxidative properties of the mutant SOD1, causes massive mitochondrial vacuolation in motor
neurones, resulting in degeneration, earlier than other neurones, triggering the onset of
weakness. The involvement of mitochondrial degeneration in the early stages is consistent
with a direct effect of toxicity, mediated by properties gained by the mutant enzyme in
catalysing redox reactions. (Beckman et al., 1993).
Until recently, it has not been possible to address this in humans, as pre-symptomatic diagnosis
was not possible. Now, with the ability to identify Cu, Zn superoxide dismutase 1, (SOD1)
mutation carriers, a group of human pre-symptomatic subjects can be studied to determine
whether there was gradual lifelong pre-symptomatic loss of motor neurones or whether
sudden catastrophic loss of motor neurones occurs just prior to the onset of clinical symptoms.
3. Familial ALS
The only forms of MND in which a clear cause has been established are the genetic variants.
20% of all familial cases are the dominantly inherited adult onset form of MND, which is
clinically indistinguishable from the sporadic form of MND. These are due to a point mutation
in the cytosolic Cu, Zn superoxide dismutase 1, (SOD1) gene on long arm of chromosome 21
(21q22.1). (Siddique & Deng, 1996). Mutations in other genes, alsin and the heavy subunit of
neurofilament (NEFH) can also result in motor neurone degeneration in humans. Two other
genes that have been investigated are the other isoforms of SOD. MnSOD (SOD2) maps to
chromosome 6q25 and is primarily located in mitochondria and extracellular SOD (SOD3)
maps to chromosome 4p15.2. Neither of these genes have yet to be linked to FALS. (Hand &
Rouleau, 2002). There is however genetic heterogeneous and other causal genes remain to be
found to explain the vast majority of FALS cases. (Siddique et al., 1989).
The initial study to establish a causal link between the SOD1 gene and familial MND (FALS)
identified a total of 11 missense mutations in two exons studied in 13 autosomal dominant
MND families. (Rosen et al., 1993). This led to an explosion of SOD1 gene screening in MND
pedigrees. To date 112 different mutations in the SOD1 have been found which can lead to
changes throughout the protein. There have been 99 substitutions, 5 polymorphisms, 3
insertions, 4 deletions and 1 compound mutation types identified. Mutations have been
identified in all five exons of the gene. These include 20 on exon 1, 13 on exon 2, 8 on exon 3,
39 on exon 4 and 29 on exon 5 (Figure 1). There have also been 2 non-exon mutations identified
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on intron 4 and intron 1 and 14 ‘apparently’ sporadic cases described with 6 different SOD1
mutations. (Shaw et al., 1998).
Figure 1. Number of SOD1 mutations identified for each exon
Most are autosomal dominant in inheritance, but there is one confirmed autosomal recessive
mutation, the D90A mutation in exon 4. This is unique in that it exists in dominant families in
a heterozygous state, but in a number of pedigrees, specifically those of Scandinavian ancestry,
homozygous mutations are required for disease. (Andersen et al., 1997).
Mutations in the heavy polypeptide 200kDa subunit of neurofilaments (NEFH) have been
identified in sporadic MND cases, (Figlewicz et al., 1994) and in one FALS case. (Al-Chalabi
et al., 1999). Accumulation of neurofilaments in cell bodies and axons of motor neurons is a
pathological hallmark of early stages of many neurodegenerative diseases. These mutations
lie in the region of the protein involved in cross-linking and thus may disrupt normal aggre‐
gation of filaments. Thus far, 1 insertion and 5 deletion mutations have been identified on exon
4. Analysis of the NEFH locus on chromosome 22 however has failed to detect linkage in MND
families. (Vechio et al., 1996). Genome search on a large pedigree with autosomal dominant
juvenile onset MND found strong evidence for linkage to chromosome 9q34 (ALS4). The
average age of onset is 17 years, with slow progression of disease. (Chance et al., 1998). There
is also an autosomal recessive, juvenile onset MND, with linkage to a locus on chromosome
15 (ALS5). (Hentati et al., 1998).
The other 90% of all MND patients have the sporadic form. There is no recognisable phenotypic
difference between FALS and sporadic MND. The male: female ratio is 1:1 in FALS and 1.7:1
in sporadic MND. (De Belleroche et al., 1995). This decreases with increasing age of onset and
approaches 1:1 after the age of 70. (Haverkamp et al., 1995). The site of onset is variable.
Survival does not seem to be affected by age or gender, but rather the site of symptom onset.
Generally, bulbar onset disease has a worse prognosis, and upper limb onset is more favour‐
able. (Mulder et al., 1986).
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It has be postulated that sporadic MND may be the final development of a chain of events that
may be set in motion at one or more places in the central nervous system by endogenous and
exogenous causes, or both. The aetiology of MND however remains unknown and is probably
multifactorial. (Eisen 1995). There is no evidence to support the cause of sporadic MND being
due to accumulation of heavy metals in the environment, (Needleman, 1997), deficiencies or
excess of essential trace metals, (Mena et al., 1967) or exposure to environmental poisons and
industrial solvents. (Leigh, 1997). There is also no evidence to support the cause of sporadic
MND being due excessive physical activity or antecedent trauma.
4. Possible patterns of motor neurone loss
In normal healthy individuals, it has been shown that there is little loss of functioning motor
neurones before the age of 60. The normal aging process then accounts for loss of approxi‐
mately 3.9% of the original motor neurone pool per annum after the age of 60. (Brown, 1972).
In this situation, the number of motor neurones remain fairly constant up to the age of 60, after
which there is a gradual steady decline with age.
MND may be due to a slow attrition of motor neurones over time (Pattern 1 in Figure 2). If this
were the case, pre-symptomatic motor neurone loss may be identifiable in SOD1 mutation
carriers, as eventually there may be a gradual decline over time (Figure 2).
Another possible course of MND is that normal numbers of motor neurones are maintained
until sudden, rapid multi-focal cell death of motor neurones occurs, corresponding with the
development of symptoms (Pattern 2 in Figure 2). If this situation, it would be expected that
SOD1 mutation carriers have a normal number of motor neurones during the pre-symptomatic
phase. In this case, cell death occurs as neurones gradually accumulate damage, secondary to
the mutation, which ultimately overwhelms cellular homeostasis. This is the cumulative
damage hypothesis. (Clarke et al., 2000).
One of the mechanisms most frequently proposed to underlie cumulative damage is oxidative
stress, in which an imbalance between the production of reactive oxygen species and cellular
antioxidant mechanisms results in chemical modifications of macromolecules, thereby
disrupting cellular structure and function. (Robberecht, 2000). A key prediction of the cumu‐
lative damage hypothesis is that the probability that any individual neurone will become
committed to apoptosis increases as damage accrues within it. A mutant neurone in an older
patient will have accumulated a greater amount of damage and is therefore be more likely to
die than in a younger patient. Consequently, early in the course of disease, the chance of a cell
containing a sufficient amount of damage to initiate apoptosis is small, and the rate of cell loss
is correspondingly low. However, as the amount of intracellular damage increases, the chance
that a cell will die also increases
It has been shown that the kinetics of neuronal death in a number of inherited neurodegener‐
ative diseases was best explained by models in which the risk of cell death remains constant
throughout life of the neurone and that cell death occurred randomly in time and was
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independent of any other neurone. This implies a “one-hit” biochemical phenomenon in which
the mutant imposes an abnormal mutant steady state on the neurone and a single catastrophic
event randomly initiates cell death and apoptosis. The principal features of the mutant steady
state are that the living mutant neurones function very well for years or even decades and that
the predominant feature of the mutant neurones is that they are all at a risk of death. This
argues against the multiple environmental factors hypothesis as a cause of MND, as a random
process is probably responsible for the initiation of disease. (Clarke et al., 2001).
5. Cu/Zn Superoxide Dismutase (SOD1) mutations
Linkage studies for familial MND (FALS) on chromosome 21q22.1 led to the identification of
point mutations in the gene for Cu/Zn superoxide dismutase (SOD1) as a cause of MND.
(Siddique 1991). Superoxide (O2-) is an unstable and highly active molecule, which causes
Figure 2. Diagrammatic representation of possible patterns for motor neurone loss in an individual.
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oxidation of cell constituents either directly or through toxic and stable derivatives. The major
superoxide dismutase activity in cytoplasm is from SOD1, which consists of 5 small exons that
encode 153 highly conserved amino acids with a molecular weight of 16Kda. SOD1 is a
homodimer. Within each monomer, there is an active site containing one atom each of copper
and zinc. (Radunovic & Leigh, 1996).
The most common SOD1 gene mutation seen in FALS is an alanine to valine shift at codon 4
(Ala4Val). This accounts for 50% of all mutations in the USA. (Rosen, 1993). Of all the clinical
variables, only bulbar onset and three specific mutations seem to influence age of onset of
MND. Bulbar patients are older when their illness begins, whereas the Gly37Arg and Leu38Val
mutations predict an earlier age of onset.). Leu38Val is associated with the earliest onset (mean
35.5 years) and Ile113Thr with the latest onset (mean 58.9 years).
In terms of survival, Ala4Val correlated with the shortest survival of 1.5 years. Whereas,
Gly37Arg, Gly41Asp, and Gly93Ala mutation predicted longer survival. The mutations that
predict earlier onset are not the same as those that correlate with shortest duration of disease.
(Cudkowicz et al., 1997). This suggests that the factors that influence onset of disease differ
from those that influence the rate of progression of the disease.
Determining the mechanism by which mutations in the Cu/Zn superoxide dismutase (SOD1)
gene triggers the destruction of motor neurones causing MND remains a challenging and
complex problem. Five primary hypotheses have been postulated for the pathogenesis of FALS
(Figure 3). (Hand & Rouleau, 2002). At present the favoured hypotheses is that the mutation
causes disease as a result of a toxic gain of function by the mutant SOD1 provoking selective
neurotoxicity, probably disrupting the intracellular homeostasis of copper and/or protein
aggregation. (Clevland, 1999).
The mutant SOD1 enzyme has altered reactivity with certain substrates, (Noor et al., 2003), in
addition to the major superoxide dismutase activity. The SOD1 enzyme catalyses the reduction
of hydrogen peroxide (H2O2), therefore acting as a peroxidase. This leads to the formation of
hydoxyl radicals that can also alter the neurofilament network. Motor neurones have high-
energy requirements and thus contain many mitochondria that generate superoxide radials
(O2-) through normal metabolism. SOD1 is an anti-oxidant defence which catalyses conversion
of superoxide free radical anion (O2-) to hydrogen peroxide (H2O2), which is reduced to H2O
and O2 by catalse. Mutations at SOD1 binding sites, alter the redox behaviour of the enzyme
and destabilise the SOD1 ligand, leading to increased oxidative damage as hydrogen peroxide
and its derivatives are toxic to the cell. (Yim et al., 1990).
This supports the hypothesis that the pathogenesis of SOD1 related FALS may be due to
increased peroxidase activity of mutant SOD1 resulting in oxidative damage mainly to lipids
of the cell membrane.
Mapping of the mutation sites predicted that these mutations destabilise the protein structure,
leading to a less active enzyme i.e. “loss of function”. This is however not supported by the
fact that transgenic mice over expressing SOD1 gene developed disease similar to MND in
humans, while those over-expressing normal SOD1 remained unaffected. This suggests that
the mutant mice develop the disease independent of the level of SOD1 activity and suggests
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that the mutant protein itself is selectively toxic to motor neurones and that there is a “gain of
toxic function” rather than a “loss of function”. (Gurney et al., 1994). Also, although most
mutations in SOD1 gene cause decrease in steady state of cytosolic SOD1 activity, Gly37Arg
and Asp90Ala, have no significant decrease in SOD1 activity. (Shaw et al., 1998).
As most SOD1 mutations destabilise SOD1 protein (except Asp90Ala), it is possible that the
mutant protein, with altered conformation may become unstable and precipitate to form
aggregates or inclusions in motor neurons. These aggregates may then disturb normal cell
function and lead to cell death. They are easily formed when SOD1 protein stability is
decreased because this protein exists in large amounts accounting for 0.5-1% of total cytosolic
protein in neurons. Alternations in the length of the coding sequence, folding, solubility or
degradation results in the formation of aggregates. (Yim et al., 1990). Structural changes of
mutant SOD1 may distort the rim of the electrostatic guidance channel and allow the catalytic
site to become exposed and shallow. Molecules that are normally excluded may gain access to
the catalytic reactive site. This results in less buffering of copper and zinc, which then become
neurotoxic. (Radunovic & Leigh, 1996).
Figure 3. Pathways that have been implicated in motor neurone cell death in amyotrophic lateral sclerosis (Repro‐
duced from Hand CK. Familial Amyotrophic Lateral Sclerosis. Muscle Nerve 2002; 25:137).
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The nitric oxide (NO) produced by nitric oxide synthase (NOS) reacts spontaneously with O2-
to generate peroxynitrite (ONOO-), which nitrosylates proteins leading to damage. Excess NO
may also cause an increase in O2- production by inhibition of mitochondrial electron flow,
resulting in further generation of peroxynitrite. This facilitates nitrosylation of tyrosine
residues of critical cytosolic proteins thus injuring cells. This reaction is copper dependent. The
source of free copper may be mutant SOD1, which cannot accept the ion from the copper
chaperone (CCS) protein. Mutant SOD1 possibly exhibit metal mediated cytotoxicities by
disrupting the intracellular homeostasis of Cu and Zn, which are potential neurotoxins.
(Gurney & Tomasselli, 1994).
The target proteins for nitrosylation include the neurofilament (NF) subunits, which may result
in abnormal NF accumulation and subsequent disruption of the NF network and axonal
transport, as there is a high neurofilament content in motor neurones. It has also been dem‐
onstrated that transgenes encoding mutant NF subunits can directly cause selective degener‐
ation and death of motor neuones. (Cleveland, 1999). Conformational changes have been
described in the mutations, Ala4Val, Gly37Arg and His6Arg that may affect the rim of the
electrostatic guidance channel coded by exon 3. (Sjalander et al., 1995).
Glutamate is released from the presynaptic terminal activates the glutamate receptor on the
postsynaptic cell membrane. It is then cleared from the synaptic cleft by specific glutamate
transporters such as EAAT2. (Trotti et al., 1999). Astrocyte (glial cell) dysfunction may result
in selective loss of EAAT2, interfering with the normal clearance of glutamate and allowing it
to accumulate in the cell membrane and continue to activate the receptor. (Bruijin et al., 1997).
Once activated, the glutamate receptor causes a calcium influx and a cascade of toxicity. The
neurone does not have the capacity to buffer this efficiently due to a deficiency in calcium
binding proteins (CBP’s). This results in disturbances in mitochondrial metabolism and as a
consequence, motor neurone cell death. (Beal, 1996).
To date, the only effective approved treatment for amyotrophic lateral sclerosis is Riluzole,
(Cheah et al., 2010), which has a neuroprotective role, possibly due to pre-synaptic inhibition
of glutamate release. (Doble, 1996). Treatment of human ALS patients or transgenic Cu, Zn
superoxide dimutase 1 (SOD 1) mice, most commonly produce a modest but significant
increase in survival. (Bensimon et al., 1994). It has also been shown to have a small beneficial
effect on bulbar function, but not muscle strength. (Miller et al., 2007).
Apoptosis is characterised by a series of cellular changes leading to non-inflammatory cell
death. Mitochondrial involvement in the apoptotic pathway also leads to the release of
cytochrome c, an activator of the initiator caspase-9, which in turn activates caspase-3, which
are executioners in the breakdown of essential cellular proteins. There is evidence that the
mutant SOD1 transgene causes motor neurone death in mice through caspase-mediated
programmed cell death. (Li et al., 2000). This may then be a target for inhibiting the apoptotic
cascade, as it has been shown in a SOD1 transgenic mouse model that a small peptide caspase
inhibitor (zVAD-fmk), prolonged survival after onset of disease by nearly 70%. (Kosti et al.,
1997). It has also been reported that there are elevated levels of bax protein in MND spinal
motor neurones, which promotes apoptosis. (Mu et al., 1996).
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6. Methods
The Department of Molecular Medicine at Concord hospital had a large database of family
members with a known family history of MND, who had blood samples collected for DNA,
as part of a previous linkage study. From this database, family members were contacted by
telephone by the department’s genetic counsellor and informed about the study.
The regional committees for Ethics in Medical Research from Central Sydney Area Health
Service, Royal North Shore Hospital and Prince Charles Hospital, approved this study.
All individuals participated without knowledge of their mutation status and on the under‐
standing that this would not be revealed to them. Subjects were also aware that the results
obtained from the study would not be available to them and that the information would only
be used for research purposes. New consents were obtained from all individuals who partici‐
pated in the study. The neurologist performing the MUNE studies also had no knowledge of
their mutation status. The mutation status was only used in the final analysis of results.
Subsequently, they were divided into “SOD1 negative family controls” and “asymptomatic
SOD1 mutation carriers”.
In addition, studies were also carried out on normal individuals, such as department techni‐
cians, spouses of SOD1 family members and individuals from the general population who
attended MND support meeting and had an interest in helping to advance research into MND.
This group was used as “population controls”, to test the validity and reproducibility of the
MUNE technique used.
Sporadic MND subjects were also initially studied once the MUNE technique had been
validated to demonstrate that the MUNE technique used was able to detect a loss of motor
neurones, when present. These were used as “positive controls”.
6.1. Motor unit number estimation
Motor unit number estimation (MUNE) estimates the number of functioning lower motor
neurones innervating a muscle or a group of muscles and is a measure of the primary patho‐
logic process of motor neurone loss. The concept of motor unit number estimation (MUNE)
originated in 1967. At the time there was no satisfactory method of assessing the extent of
denervation in muscles during life. Analysis of the density of the electromyographic interfer‐
ence pattern during maximal effort was not quantitative, and required the full co-operation of
the patient.
The principle of MUNE is that if one can measure the mean single motor unit amplitude
(SMUP), it is possible to obtain an estimate of the total number of motor units in the muscle.
The results achieved were comparable with estimates of alpha motor fibres obtained by
counting axons in specimens of motor nerves. (McComas, 1971).
MUNE has been performed in a number of different ways, each with their advantages and
limitations. (Stein & Yang, 1990). The choice of technique depends on the speed and simplicity
of the technique, as well as its accuracy and reproducibility. Some methods sample a very small
The Role of the Statistical Method of Motor Unit Number Estimation (MUNE) to…
http://dx.doi.org/10.5772/56559
193
proportion of the number of motor units innervating a muscle (typically 10-20). The coefficient
of variation associated with different methods range from 10-45%. (McComas, 1991). If the
variability is too large, then the technique cannot be used to follow motor unit loss reliably
over time.
The way the average single motor unit potential (SMUP) size is obtained distinguishes the
several techniques available. Most employ electrical stimulation of the motor nerve to
determine the sizes of the SMUP, but a few use needle EMG.
Each method measures both the average size of the potentials generated by single motor units
- single motor unit potentials (SMUP) and the size of the compound muscle action potential
(CMAP) obtained with maximal stimulation of a motor nerve.
The motor unit number estimate is calculated by:
MUNE= Maximum CMAP amplitude (or area)Average single motor unit potential (SMUP) amplitude or area.
Whereas the methods of measuring the average SMUP differ, they have common assumptions
about the measurement of the supramaximal CMAP and the measurement of the average
SMUP.
i. Maximal stimulation of any peripheral motor nerve activates all the muscles inner‐
vated by that nerve distal to the point of stimulation. Therefore, measurements of the
CMAP are the summation of activity from multiple muscles and the MUNE is more
accurately an estimate of the number of motor units in a group of muscles rather than
in a single muscle.
For example, the median CMAP recorded at abductor pollicis brevis (APB) is more correctly
a “thenar MUNE”, as it is a summation of the activity of APB, opponens pollicis, flexor pollicis
brevis, and to a lesser extent, the lateral lumbricals.
Extensor digitorum brevis (EDB) on the other hand, is a muscle innervated by the deep
peroneal nerve. The only source of interfering muscle action potential is from extensor hallucis
longus, which can be reduced by correct position of the stimulating electrodes. The muscle
belly is flat in profile, eliminating deeper motor units as a cause of small potentials. The
recording electrode is placed transversely across the innervation zone, resulting in a simple
biphasic negative-positive M wave.
ii. The motor unit potentials used in the calculation of the average SMUP are represen‐
tative of those generated by the total population of units. All methods, select a subset
of the total population of motor units, measure their sizes and calculate an average
SMUP for that subgroup.
iii. Finally, there is a phenomenon caused “alternation”. This refers to fluctuations in the
CMAP amplitude of the same motor unit with similar stimulation intensities. The
thresholds of the first few motor axons excited are not sufficiently separate from one
another, so that when graded increases in the stimulus intensity occur, the motor
axons excited often overlap and add more than one SMUP to the CMAP being
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recorded. This can result in an underestimation of the mean SMUP size, as it may
appear that there are 7 or 8 motor units when there are only 2 or 3 present, which in
turn results in an over-estimation of the MUNE.
6.2. Statistical MUNE method
We used the statistical electrophysiological technique of motor unit number estimation
(MUNE), (Daube, 1998), was used to estimate the number of motor units in thenar and extensor
digitorum brevis muscles. The statistical method estimates the average size of SMUP’s and the
number of motor units in a group of muscles innervated by the nerve being stimulated, based
on the normal variation of the submaximal CMAP evoked with constant stimuli. No attempt
is made to identify individual motor unit potentials. The method relies on the known relation
between the variance of multiple measures of step functions and the size of the individual
steps when the steps have a Poisson distribution. S.D. Poisson was a French mathematician
(1781-1840).
Poisson statistics are useful when the distribution arising for events occur randomly in time
or when small particles are distributed randomly in space. They have been used to calculate
the number of quanta released from a nerve terminal at the neuromuscular junction when the
individual quanta are too small to be distinguished, as in myasthenia gravis. (Lomen-Hoerth
& Slawnych, 2003).
In pure Poisson statistics, the size of a series of measurements is multiples of the size of a single
component. In a Poisson distribution there is a discrete asymmetrical distribution in which
responses are found at some levels and others where there are no responses (Figure 4). (McNeil,
1996).
A pure Poisson distribution has decreasing numbers at higher values. In Poisson distribution,
the variance of these 30 measurements is equal to the size of the individual components making
up each measurement. The variance can thus provide an estimate of the average size of the
SMUP’s.
The statistical method looks only at variance of the CMAP and does not require identification
of individual components. It can be used when the sizes of SMUP’s are too small to be isolated.
The statistical method assumes that each motor unit has a similar size and that it is the same
size each time it is activated.
Sequences of 30 submaximal stimuli are given. The inherent variability of the threshold of
individual axons causes variations in the size of the CMAP. The average change in the
submaximal CMAP amplitude caused by alternation (addition and subtraction of motor
axons) is derived by Poisson statistics.
The occurrence of alternation with changing units that are activated does not modify the
accuracy of the statistical method, because the method is a statistical measurement, a different
result is found with each series of 30 stimuli. Therefore, multiple trials are needed to obtain
the most accurate measurement. (Olney et al., 2000).
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Experimental testing with trials of >300 stimuli has shown that repeated measurement of
groups of 30 until the standard deviation of the repeated trials is <10% provides a close estimate
of the number obtained with many more stimuli.86 Estimates of the SMUP size and of the
number of motor units are also most reliable if made at multiple different stimulus intensities
to test axons with different thresholds.
MUNE is calculated with the number weighted statistical method, where the mean SMUP
amplitude at each level is multiplied by the number of motor units estimated at each level.
The steps in statistical MUNE are as follows:
1. Recording surface electrodes are applied as for standard nerve conduction studies.
2. An initial scan of the CMAP is performed using a series of 30 submaximal stimuli at 1 Hz,
increasing in equal increments to identify unusually large steps at which further infor‐
mation is required.
3. On the basis of the scan, three or four 10% stimulus ranges are identified, according to an
internal algorithm. Usually, one range includes the smallest step and the other ranges
where the steps are >15% (Figure 4).
4. At each intensity, groups of 30 responses are captured at a rate of 3Hz. Estimates are most
reliable if 10 groups of 30 responses are recorded. To minimise patient discomfort,
however, repetition is repeated until the standard error of the MUNE SMUP size is less
than 10%.
5. Statistical MUNE estimates the average size of SMUP’s and the number of motor units in
a group of muscles innervated by the nerve being stimulated, based on the normal
variation of the sub-maximal CMAP evoked with constant stimuli (Figure 5).
The statistical technique of estimating the size of the SMUP was performed using proprietary
software on a Nicolet Viking IV electromyography machine. This technique uses direct
stimulation of the motor nerve. The low frequency filter was set at 2 Hz and the high frequency
filter at 5 kHz. The gain for extensor digitorum brevis was set at 2 mV/div and for abductor
pollicis brevis studies at 5 mV/div. The sweep speed was 2 ms/div. This method had excellent
test-retest reproducibility (+/-2.8%). The method was quick to use and well tolerated.
This technique has been greatly modified since its original description, but numerous studies
have shown that MUNE can change systematically in ALS patients when used by experienced
technicians, even though evaluator bias needs to be taken into account. (Shefner et al., 2004).
The statistical MUNE method has also been shown to be unreliable in the presence of clinical
weakness due to motor unit instability. (Shefner, 2009).
Our study however was performed on asymptomatic patients, without clinical weakness.
6.3. MUNE Technique
Motor unit numbers were estimated in abductor pollicis brevis (resulting in a thenar MUNE)
and the extensor digitorum brevis (EDB) muscle. These muscles were used, as both are easily
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accessible distal muscles. The electrical activity can be recorded without interference, and in
the case of EDB, the muscle belly is flat.
Self-adhesive surface recording electrodes (G1) were placed transversely across the innerva‐
tion zone of each muscle, resulting in a simple biphasic negative-positive M wave, with G2
placed over a bony prominence. The deep peroneal nerve was stimulated just above the ankle
and the median nerve at the wrist with a surface stimulator. This was performed by strapping
 
Figure 4. An initial scan of the CMAP (right) recorded from APB muscles in response to 30 sub-maximal stimuli (x-axis)
with equal increments between threshold and maximum stimulation. On the basis of the scan, 10% stimulus ranges
are identified, according to an internal algorithm. The CMAP increments are shown at the top left and the eventual
table of results in the bottom left corner.
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the stimulating electrode onto the surface of the skin, at the point where the threshold of the
nerve to electrical stimulation was at its’ lowest. A hand-held stimulator was not used, as
reproducibility is enhanced when the stimulating electrodes are fixed to the surface of the skin.
Initially, bilateral thenar and EDB MUNE’s were obtained from all subjects. After the repro‐
ducibility phase of the study, generally only right-sided studies were performed. Once a
 
Figure 5. At each intensity level (runs 1-4), groups of 30 responses are captured at a rate of 3Hz. The CMAP ampli‐
tudes are shown at the top left, with the histogram of results at the top right. The thenar MUNE results from repeated
trials are shown in the bottom left table.
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reduction in MUNE was identified, bilateral studies were once again performed on selected
subjects. The protocol was also modified depending on the subjects’ tolerance to the procedure.
Median nerve stimulation at the wrist for thenar MUNE was generally well tolerated by most
subjects, as the stimulation intensity required to obtain an adequate response was generally
less than 20mA with duration of 0.05-0.1ms.
Peroneal nerve stimulation required for EDB MUNE resulted in slightly more discomfort, as
the nerve is located further away from the surface of the skin. The stimulus intensity required,
in some cases was up to 50-80mA with duration of between 0.1-0.3ms. Some subjects indicated
that they were unwilling to continue to participate in the study due to the discomfort caused
by performing EDB MUNE. In these subjects, only thenar MUNE’s were performed.
To assess the test-retest reproducibility of the technique, SOD1 family members and popula‐
tion controls were followed over a 1-year period, with thenar and EDB MUNE tests repeated
every 3 to 6 months. The difference between MUNE results from the first and second study,
and if possible, first and third studies were divided by the MUNE of the first study, and
expressed as a percentage change. The results were analysed using Pearson and Spearman
correlation coefficients.
All results were entered into a database and analysed using a standard statistical software
package (SPSS 9.05 for Windows). For the initial part of the study, the MUNE results from
asymptomatic SOD1 mutation carriers were grouped together. Although different mutations
in SOD1 have different effects on the progression of the disease once symptoms occur, these
different mutations do not influence on the age of onset of symptoms.67
Motor unit estimates in carriers were compared to age and sex matched family controls without
the SOD1 mutation, and sporadic (non-SOD1) MND patients. To determine whether groups
had different numbers of motor units, an unpaired t-test was used. Although there were some
outlying results, the distributions were not sufficiently skewed to contradict the use of the t-
test. Statistical significance was accepted at a p-value of <0.05.
The group of asymptomatic SOD1 mutation carriers were followed over the next 2 to 5 years,
depending on the volunteers’ motivation, both clinically and by MUNE. Results were com‐
pared to their initial baseline MUNE and the date of the study when this reduction was first
detected, was used as the date when motor neurone loss commenced.
6.4. Maximal voluntary isometric contraction testing
It has been suggested that the traditional neurological examination is inadequate for docu‐
menting motor performance impairment with reliability. (Hanten et al., 1999). Generally,
manual motor testing used in a standard neurological motor examination does not allow
objective documentation of change in performance, as it may be influenced by the patient’s
history and progress. Major changes are apparent, but subtle changes are difficult to determine
with accuracy.
There are a number of methods that have been developed to quantify maximal voluntary
isometric contraction (MVIC). It has been proposed that this is a clinically useful, reliable,
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reproducible, time efficient and quantitative measure for monitoring disease progression in
MND. (Hoagland et al., 1997). This would be surprising, given that in a slowly progressive
denervating process, patients with substantial chronic denervation could maintain normal
muscle twitch tension until loss of about 70-80% of motor units occurs. (McComas, 1971).
The methods used to quantify maximal voluntary isometric contraction have included an
electronic strain-gauge tensiometer and a hand-held Jamar hydraulic dynamometer. In this
study, maximum bilateral isometric grip strength was obtained using the Jamar hydraulic
dynamometer to determine whether this correlated with the number of functional motor
neurones in the thenar group of muscles, as measured by MUNE. Standardised (middle
handle) positioning and instructions were given to all subjects. Handgrip force was measured
with subjects in the sitting position and with the arm flexed at 90 degrees. Two trials were
performed on each hand, and the best result used for analysis. This method was used as
previous studies of grip strength reliability showed that there was no significant difference in
reliability between one attempt, the mean score of two or three attempts, or the highest score
of three attempts. (Hamilton et al., 1994).
Clinical neurological examination was performed, with power of thumb abduction, finger
flexion and finger abduction measured according to the Medical Research Council (MRC)
grading system and compared to thenar (APB) MUNE.
Felice showed that in twenty one MND patients, changes in thenar MUNE was the most
sensitive outcome measure for following disease progression, when compared to other
quantitative tests, such as CMAP, isometric grip strength, forced vital capacity and Medical
Research Council manual muscle testing. (Felice, 1997).
7. Results
7.1. Demographics
A total of eighty-eight (88) subjects (45 males and 43 females) gave informed consent. The
subjects were divided into four test groups.
1. 24 population controls;
2. 32 SOD1 negative (normal) family controls;
3. 20 asymptomatic (pre-clinical) SOD1 mutation carriers (test group),
a. 5 subjects with point mutation in exon 4, codon 100, GAA to GGA, Glu to Gly) –
glu100gly;
b. 5 subjects with point mutation in exon 4, codon 113, ATT to ACT, Ile to Thr) – ile113thr;
c. 5 subjects with point mutation in exon 5; codon 148, GTA to GGA, Val to Gly) –
val148gly;
d. 5 subjects with point mutation in exon 5, codon 148, GTA to GGA, Val to Ile) val148ile.
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4. 12 sporadic symptomatic MND patients (positive controls).
There was no statistically significant difference in age distribution between these groups, with
a range of 16 to 73 years of age.
7.2. Motor units in asymptomatic FALS (SOD1) carriers
For the initial part of the study, the baseline MUNE results were grouped together and the
means of the groups were compared. The initial aim of the study was to determine if MND
was due to a slow gradual attrition of motor neurones over time. If this were the case, the group
of asymptomatic SOD1 mutation carriers, would be expected to have a reduced number of
motor units, indicating the presence of pre-clinical motor neurone loss. Motor unit estimates
in the group of asymptomatic SOD1 mutation carriers were compared to age and sex matched
family controls without the SOD1 mutation, and sporadic (non-SOD1) MND patients. To
determine whether groups had different numbers of motor units, an unpaired t-test was used.
Statistical significance was accepted at a p-value of <0.05.
The numbers of motor units in the groups of population controls, SOD1 negative family
controls and asymptomatic SOD1 mutation carriers were similar. In population controls the
mean thenar MUNE was 148 with a range of 115 - 254, in SOD1 negative family controls was
138 with a range of 106 - 198 and in asymptomatic SOD1 mutation carriers, 144 with a range
of 109 - 199. There was no detectable difference in the mean number of thenar motor units in
the group of asymptomatic SOD1 mutation carriers compared to the group of SOD1 negative
family controls (thenar p>0.46), or population controls (thenar p>0.70) (Table 1 and Figure 6).
In population controls the mean EDB MUNE was 138 with a range of 119 - 169, in SOD1
negative family controls was 134 with a range of 107 - 180 and in asymptomatic SOD1 mutation
carriers, 136 with a range of 111 - 187.
Once again, there was no detectable difference in the mean number of EBD motor units in the
group of asymptomatic SOD1 mutation carriers compared to the group of SOD1 negative
family controls (EDB p>0.95), or population controls (EDB p>0.50) (Table 2 and Figure 7).
Thenar (APB) muscle
Cases MUNE (Range)
Population Controls 24 148 (115-254)
SOD1 Negative Family Controls 32 138 (106-198)
SOD1 Mutation Carriers 20 144 (109–199)
Sporadic MND patients 12 45 (5–84)
Table 1. Thenar (APB) motor unit number estimates (MUNE number represents mean MUNE).
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Symptomatic sporadic MND subjects showed a definite loss of motor units with fewer motor
units compared to all other groups (p<0001) with a mean thenar MUNE of 45 with a range of
5 - 84 and a mean EDB MUNE of 70 with a range of 8 - 82 (Tables 1 and 2).
There was no cross over between thenar and EDB MUNE results in symptomatic and asymp‐
tomatic subjects.
7.3. Reproducibility of MUNE technique
To assess the test-retest reproducibility of the technique, 69 of the 88 SOD1 family members
and population controls were followed over a 1-year period, with thenar and extensor
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Figure 6. Baseline thenar (APB) MUNE subdivided into study groups (The lower boundary of the box is the 25th per‐
centile, and the upper border is the 75th percentile of MUNE. The horizontal line inside the box represents the median
MUNE. The whispers represent the largest and smallest observed values, i.e. the range). Data is shown in Table 1.
Extensor Digitorum Brevis
Cases MUNE (Range)
Population Controls 13 138 (119-169)
SOD1 Negative Family Controls 30 134 (107-180)
SOD1 Mutation Carriers 14 136 (111-187)
Sporadic MND patients 9 70 (8-82)
Table 2. EDB motor unit number estimates (MUNE number represents mean MUNE).
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digitorum brevis (EDB) MUNE tests repeated every 3-6 months, depending on patient
availability. The difference between MUNE results from the first and second study, and if
possible, first and third studies were divided by the MUNE of the first study, and expressed
as a percentage change. The results were analysed using Pearson and Spearman correlation
coefficients.
The test-retest correlation of thenar MUNE in asymptomatic subjects was high with a Pearson
correlation coefficient of 0.93. The mean difference between MUNE results on separate
occasions on the same individual was +/- 3.6%, with a range of 0-11.7% (Table 3).
Number of Cases Mean MUNE
Thenar 1 88 145.7
Thenar 2 69 140.1
Thenar 3 33 140.0
Thenar Change Range (0 - 11.7%) 3.6%
Table 3. Reproducibility of mean thenar (APB) motor unit number estimates in asymptomatic subjects on separate
reviews over a one-year period.
For EDB MUNE, the Pearson correlation coefficient was also high, 0.88, with a mean difference
between MUNE results on separate occasions on the same individual of +/- 4.6%, with a range
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Figure 7. Baseline EDB MUNE subdivided into study groups (The lower boundary of the box is the 25th percentile, and
the upper border is the 75th percentile of MUNE. The horizontal line inside the box represents the median MUNE. The
whispers represent the largest and smallest observed values, i.e. the range). Data is shown in Table 2.
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of 0-15.7%. The test-retest correlation was high with a Pearson correlation coefficient of 0.91,
when groups were broken down into the different study groups.
7.4. Maximal voluntary isometric contraction
Maximal voluntary isometric contraction (MVIC), using the Jamar hand dynamometer was
used to measure isometric grip strength to determine whether this correlated with the number
of functional motor neurones in the thenar group of muscles as measured by MUNE. Isometric
grip strength tests, thenar MUNE and MRC power were performed on 69 asymptomatic
subjects twice within a 3-6 month period to assess the test-retest reproducibility of this
technique. Pearson correlation coefficients between study 1 and study 2 of right hand grip
strength was 0.941, left hand grip strength 0.910 and thenar MUNE results 0.937. These results
indicate that the reproducibility of these techniques was high.
Right hand grip strength correlated with left hand grip strength, with Pearson correlation
coefficients of 0.959 and Spearman correlation coefficients of 0.956 Two-way analyses of
variance showed a no significant difference between the right and left hands (Figure 8). There
was no correlation between right grip strength and right thenar motor unit number, with
Pearson correlation coefficients of 0.483 and Spearman correlation coefficient of 0.34 (Figure 9).
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Figure 8. Graph showing the correlation between right and left handgrip
7.5. Detection of pre-symptomatic motor neurone loss in SOD1 mutation carriers
The MUNE results, after validating their reproducibility, were used as a baseline to follow the
number of motor units over time in individual pre-symptomatic SOD1 mutation carriers over
the next 2-5 years, to determine whether pattern of motor neurone loss is either a slow attrition
of motor neurones over time or whether normal numbers of motor neurones are maintained
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until sudden, rapid multi-focal cell death of motor neurones occurs, corresponding with the
development of symptoms.
During the course of the study, 5 of the SOD1 mutation carriers developed leg weakness. A
significant fall in motor unit number was detected in these 5 SOD1 mutation carriers, were
there was a detectable reduction of motor units, 4-10 months prior to the onset of weakness
and the diagnosis of familial ALS being made. There was no detectable loss of motor units in
the other 15 SOD1 mutation carriers or in the group of SOD1 mutation negative relatives,
during the study period.
In individual cases, there was:
51% loss of motor units, 4 months prior to onset of weakness in Case 1
37% loss of motor units, 10 months prior to onset of weakness in Case 2
28% loss of motor units, 6 months prior to onset of weakness in Case 3
46% loss of motor units, 6 months prior to onset of weakness in Case 4
68% loss of motor units, 8 months prior to onset of weakness in Case 5
There was further motor unit loss as weakness progressed, at which point the diagnosis of
MND was confirmed.
7.5.1. Case study 1
A 43-year-old sister of case 1. She had the same strong family history of ALS, with a point
mutation in SOD1 gene at val148gly. Her pedigree is shown in Figure 10. She was asympto‐
matic at the time of recruitment with a normal neurological examination, and no evidence of
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Figure 9. Scatter graph showing the lack of correlation between right handgrip and right thenar (APB) MUNE
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wasting, weakness or fasciculation. Her right and left thenar MUNE’s remained stable for the
first 2½ years of the study at around 115-120 motor units. Progress MUNE results are shown
in Table 4 and Figures 11.
Over the next 6 months, there was a reduction in her right thenar MUNE to 96 (20%) and her
left thenar MUNE to 89 (19%), with no detectable weakness. Her right EDB MUNE also
dropped from 111 to 92 (17%), but she only had detectable weakness 10 months later of MRC
grade 4+/5 in right dorsiflexors, at which time her right EDB MUNE had dropped further to
71 motor units (35%). The left EDB MUNE also dropped from a baseline of 112 (2 years
previously) to 89 (20%), but with no detectable weakness.
An independent neurologist performed needle EMG examination, which showed high
amplitude motor units with reduced recruitment in vastus medialis, tibialis anterior and
extensor carpi radialis longus, bilaterally but no fibrillation potentials were seen. It was felt
that these changes were not enough to make the diagnosis of ALS.
In view of her strong family history, a presumed diagnosis of familial ALS was made and she
was commenced on Riluzole in February 2002.
Over the next 3 years, her EDB MUNE results have stabilised. Her weakness has not progressed
significantly. In February 2004, she still had MRC grade 4+/5 power of her right dorsiflexors
and no symptomatically apparent weakness in her left dorsiflexors or upper limbs.
Figure 10. Pedigree of cases 1, 2 and 3
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7.5.2. Case study 2
A 57-year-old man with a strong family history of ALS dating back 3 generations, had a point
mutation in exon 4, codon 100, GAA to GGA, Glu to Gly) – glu100gly. He was initially recruited
into the study in 1998, but as he was unable to tolerate the EDB MUNE test, he elected not to
continue to participate in the study. He represented 11 years later with a 3 month history of
lower limb weakness, which he noticed only when he walked long distances and up stairs. He
had also been experiencing lower limb cramps and muscle fasciculations for years.
On examination, he had no evidence of wasting, but there were muscle fasciculations seen in
his right quadriceps. His tone was normal in the upper and lower limbs and he had MRC grade
5/5 power in all muscle groups, proximally and distally. His sensory examination was normal
to touch, vibration and position. His gait was normal.
Nerve conduction studies performed by independent neurologist were normal, with no
evidence of a large fibre peripheral neuropathy and normal CMAP amplitudes. Needle EMG
studies was also normal, with no evidence of active or chronic denervation in bilateral distal
and proximal muscles sampled. Using the same MUNE machine and computer algorithm, as
1998, a reduction in his APB MUNE was detectable. Despite the “normal EMG” findings, a
presumptive diagnosis of fALS was made. He was commenced on Riluzole therapy 50 mg
twice a day. Within 3 months, he noticed an improvement in the symptoms and there was a
detectable improvement in MUNE by 40-52%. He was able to walk up stairs easier, walk 100
metres without stopping and lower limb cramps and fasciculations disappeared. Unfortu‐
nately, due to poor tolerance, further studies have not been possible. MUNE results are shown
in Table 5.
Months pre and post -42 -40 -37 -29 -20 -10 0 +11 +21 +27
weakness 1st detected
Date of study Oct-98 Dec-98 Mar-99 Nov-99 Jul-00 Jan-01 Nov-01 Oct-02 Aug-03 Feb-04
R Handgrip 60 60 65 65 60 70 65 65 65 65
R Thenar MUNE 111 111 117 119 120 114 96 97 86 85
L Handgrip 60 55 60 65 63 65 65 60 60 60
L Thenar MUNE 117 119 111 89 86 79 81
R EDB power 5/5 5/5 5/5 5/5 5/5 5/5 4+/5 4+/5 4+/5 4+/5
R EDB MUNE 104 111 119 108 104 92 71 75 75 65
L EDB power 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5
L EDB MUNE 112 89 80 80 81
Table 4. Case 1 progressive handgrip, dorsiflexion power and thenar and EDB MUNE results
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7.5.3. Case study 3
A 43-year old lady with an extensive family history of ALS dating back 4 generations, had a
point mutation in exon 5, codon 148, GTA to GGA, Val to Gly) – val148gly. She presented with
generalised muscle fasciculations, but no weakness or cramps.
On examination, she had no wasting or fasciculations. Her tone, power, reflexes and sensation
in the upper and lower limbs were normal. Her gait was steady and she was able to walk on
her heels and toes. Tandem walking was normal and Romberg’s sign was negative.
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Figure 11. Progressive results of case 1 showing the change in APB and EDB motor unit estimates over time in relation
to handgrip strength and power. There is a reduction of APB and EDB MUNE even though strength has remained sta‐
ble.
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Nerve conduction studies  performed by independent  neurologist  were  normal,  with  no
evidence  of  a  large  fibre  peripheral  neuropathy.  Needle  EMG studies  was  also  normal,
with no evidence of active or chronic denervation in bilateral distal and proximal muscles
sampled.
On her initial MUNE testing, results were within normal values, but 5 months later, there was
a detectable reduction in her MUNE’s from baseline of between 13-23%. As the MUNE change
was greater than our re-retest reliability limits (<5%), a presumptive diagnosis fALS was made
and commenced on Riluzole therapy. This resulted in an improvement in her fasciculations
and MUNE’s over the next 6 months, 14-41%. Her MUNE results have remained stable over
the next 12 months. Progress MUNE results are shown in Table 6.
7.5.4. Case study 4
A 47-year-old lady with a family history of dominantly inherited non-SOD 1 ALS, (father aged
68 and brother aged 45, both died of ALS). A point mutation in the SOD 1 gene has not been
currently detected. She presented with a 1-year history of generalised muscle fasciculations
and occasional lower limb cramps. She had generalised tiredness and muscular aches and
pains, but no weakness, numbness or paraesthesia. Her gait was steady. As a result of her
symptoms, she ceased work in March 2004.
May-98 July-09 Nov-09
Months Baseline 13 months 4 months
Riluzole commenced
R Handgrip 105 95 80
L Handgrip 110 105 90
R APB MUNE 198 86(56% decrease)
125
45% increase)
L APB MUNE 88 124
R ADM MUNE 110 95
L ADM MUNE 85
R EDB MUNE Not tolerated 59 90(52% increase)
L EDB MUNE 67 94(40% increase)
Needle EMG Normal Normal
Table 5. showing progressive handgrip, dorsiflexion power, thenar and EDB MUNE and needle EMG results of Case 2
(Normal EMG refers to the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment)
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On examination, she had no evidence of wasting, but there were generalised fasciculations,
especially in the triceps and quadriceps regions. Her tone was normal in the upper and lower
limbs. She had no clinical weakness with MRC grade 5/5 power in all muscle groups, proxi‐
mally and distally. Her sensory examination was normal to touch, vibration and position. Her
reflexes were all present and symmetrical. Her gait was normal, as she was able to walk on
her heels and toes. She was able to perform tandem walking and Romberg’s sign was negative.
Nerve conduction studies performed by independent neurologist were normal, with no
evidence of a large fibre peripheral neuropathy. Needle EMG studies was also normal, with
no evidence of active or chronic denervation in bilateral distal and proximal muscles sampled.
Initial EDB MUNE was reduced with normal APB MUNE’s. Despite this, a clinical diagnosis
on fALS was not made given her normal needle EMG study, and she was observed over the
next 6 months. Over this time, she developed MRC grade 4/5 weakness of ankle dorsiflexion,
bilaterally and her EDB MUNE dropped by 14-20%. Despite this reduction, compound muscle
action potential amplitudes were maintained. Needle EMG studies were repeated and once
again normal there was no spontaneous activity (fibrillation potentials) and motor unit
recruitment was normal, despite the presence of weakness.
Given her family history, a presumptive diagnosis of non-SOD 1 fALS was made and com‐
menced on Riluzole therapy. This resulted in an improvement in clinical symptoms of
tiredness and fasciculations, allowing her to return to work. Her EDB MUNE improved by
34-60%, and increased further over the next year. Despite this, her treating neurologist
considered this was a placebo effect and ceased Riluzole. Within 2 weeks, her generalised aches
Sept-08 Feb-09 Aug-09 Aug-10
Months Baseline 5 months 6 months 12 months
Riluzole commenced
R Handgrip 65 70 68 65
L Handgrip 62 70 62 65
R APB MUNE 126 109(13% decrease)
124
(14% increase) 131
L APB MUNE 136 105(23% decrease)
123
(17% increase) 124
R EDB MUNE 107 9718% decrease)
134
(38% increase) 134
L EDB MUNE 104 90(13% decrease)
127
(41% increase) 117
Needle EMG Normal
Table 6. showing progressive handgrip, dorsiflexion power, thenar and EDB MUNE and needle EMG results of Case 3
(Normal EMG refers to the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment)
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and pains and fasciculations recurred. Her subsequent MUNE study was blinded, as the
operator was unaware that Riluzole had been ceased and found that her EDB MUNE’s had
reduced once again. She then had a 3rd needle EMG study, which was once again normal. She
also had a MRI scan of her brain and full spine that showed no significant abnormality. She
was recommenced on Riluzole, which resulted in a slow and steady improvement in her
MUNE, which she has been maintained. Progress MUNE results are shown in Table 7 and
Figure 12.
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Reduced 
dose to daily
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back to bd
Figure 12. showing progressive thenar and EDB MUNE changes in relation to changes in the dose of Riluzole in Case 4
8. Conclusion
Motor neurone disease (MND) is a group of fatal, progressive neurodegenerative disorders,
with an overall median survival is approximately 4.0 years from the onset of symptoms. By
the time most patients with MND are aware of clinical weakness and seek review by their
primary physician or neurologist, a significant proportion of motor units have already been
lost. Early detection of motor neurone loss in clinically apparently unaffected muscles is
therefore important to establish an early diagnosis of the condition.
Motor unit number estimates in the group of asymptomatic SOD1 mutation carriers were
compared to age and sex matched family controls without the SOD1 mutation, and sporadic
(non-SOD1) MND patients. There was no detectable difference in the number of thenar motor
units in the group of asymptomatic SOD1 mutation carriers compared to the group of SOD1
negative family controls (thenar p>0.46), or population controls (thenar p>0.70).. In addition,
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Mar-04 Oct-04 Apr-05 Nov-05 Mar-06 Jun-06
Months Baseline 7 months 6 months 7 months 4 months 3 months
Riluzole changes RiluzoleStarted
Riluzole
Ceased
Riluzole Recommenced
Apr-06
R Handgrip 50 20 50 40 40 35
R Thenar MUNE 151
96
(36%
decrease)
113 134 126 133
L Handgrip 40 20 40 38 40 30
L Thenar MUNE 131 105 105 121 118 124
R EDB power 5/5 4/5 4/5 4/5 4/5 4/5
R EDB MUNE 79
63
(20%
decrease)
84
(33% increase)
130
(34%
increase)
106
99
(23%
decrease)
L EDB power 5/5 4/5 4/5 4/5 4/5 4/5
L EDB MUNE 69
59
(14%
decrease)
92
(56% increase)
147
(60%
increase)
98
90
(39%
decrease)
Needle EMG Normal Normal Normal
Date of study Dec-06 Jul-07 Mar-08 Sept-08 May-09 Nov-09 Apr-10
Months 6 months 7 months 8 months 6 months 8 months 6 months 5 months
Riluzole changes
Riluzole Daily Riluzole
BD
R Handgrip 55 45 25 34 40 40 40
R Thenar MUNE
126 132 92
(30% decrease)
124 123
(34%
increase)
117 123
L Handgrip 50 45 25 35 45 30 32
L Thenar MUNE
122 131 89
(32% decrease)
130 129
(45%
increase)
126 128
R EDB power 4/5 4/5 4/5 4+/5 4/5 4+/5 4+/5
R EDB MUNE
124
(25%
increase)
132 93
(30% decrease)
100 110
(18%
increase)
111 121
L EDB power 4/5 4/5 4/5 4+/5 4+/5 4+/5 4+/5
L EDB MUNE
117
(30%
increase)
146 88
(40% decrease)
107 126
(43%
increase)
123 120
Table 7. showing progressive handgrip, dorsiflexion power, thenar and EDB MUNE and needle EMG results of Case 4
(Normal EMG refers to the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment)
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there was no detectable difference in the number of EBD motor units in the group of asymp‐
tomatic SOD1 mutation carriers compared to the group of SOD1 negative family controls (EDB
p>0.95), or population controls (EDB p>0.50). Symptomatic sporadic MND subjects showed a
definite loss of motor units with fewer motor units compared to all other groups (p<0.001).
There was no overlap between MUNE results in symptomatic and asymptomatic subjects.
These results indicate that the group of asymptomatic carriers of the SOD1 mutation have no
significant difference in the number of motor neurones, when compared to age and sex
matched controls. All carriers had a full complement of motor neurones during the asympto‐
matic phase, indicating that mutation carriers have normal survival of motor neurones and
that symptomatic MND is not the end result of a slow attrition of motor neurones. This implies
that gradual pre-symptomatic loss of motor neurones does not occur in asymptomatic SOD1
mutation carriers. This supports the observation that sudden, catastrophic loss of motor
neurones occurs immediately prior to the onset of symptoms and the development of the
disease, rather than a gradual attrition of motor neurones over time. These results suggest that
there may be a biological trigger initiating rapid cell loss, just prior to the onset of symptoms.
This observation is an important contribution to the current understanding of the pathogenesis
of MND. (Aggarwal & Nicholson, 2001).
The statistical MUNE technique was used for the study. This technique has been greatly
modified since its original description, but numerous studies have shown that MUNE can
change systematically in ALS patients when used by experienced technicians, even though
evaluator bias needs to be taken into account. It has been suggested that the statistical MUNE
is unreliable in the presence of clinical weakness due to motor unit instability. (Shefner, 2009).
The difference is that our study was performed on asymptomatic patients, without clinical
weakness.
MUNE has been performed in a number of different ways over the years, each with their
advantages and limitations. The choice of technique depends largely on the speed and
simplicity of the technique, as well as its accuracy and reproducibility. The way the average
single motor unit potential (SMUP) size is obtained distinguishes the several techniques. Most
employ electrical stimulation of the motor nerve to determine the sizes of the SMUP, but a few
use needle EMG. The statistical MUNE technique was used for the study. (Daube, 1995). This
technique has been compared to the multiple point stimulation method and found to be more
reproducible (7% vs. 12%) and faster to administer. (Lomen-Hoeth & Olney, 2000). The
technique has been greatly modified since its original description, (Shefner et al, 2004), but
numerous studies have shown that MUNE can be used to monitor change in ALS patients
when used by experienced technicians, even though evaluator bias needs to be taken into
account. (Shefner et al., 2004).
There have been studies performed indicating that the statistical MUNE is unreliable in the
presence of clinical weakness due to motor unit instability in ALS. (Shefner et al., 2011). In our
previous study, we showed that there was no detectable difference in the number of motor
units in 19 SOD 1 mutation carriers as a group, compared to their 34 SOD 1 negative family
controls (APB p>0.46 and EDB p>0.95), or 23 population controls (APB, p>0.70 and EDB,
p>0.50). (Aggarwal & Nicholson, 2001). It also showed that MUNE may be used as a reliable
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method of pre-symptomatic detection of motor unit loss in SOD1 mutation carriers. Following
69 SOD1 family members and population controls over a 1-year period, with thenar and EDB
MUNE tests repeated every 3 to 6 months, assessed the test-retest reproducibility of the
technique. The mean difference between thenar MUNE results on separate occasions in
asymptomatic subjects was +/- 3.6%, with a range of 0-11.7%, and +/- 4.6%, with a range of
0-15.7% in EDB MUNE. Our test-retest correlation was high, with Pearson correlation coeffi‐
cients of 0.93 for APB MUNE and 0.78 for EDB MUNE. (Aggarwal, 2009). This indicates that
there is reproducibility of our statistical MUNE technique, despite recent revisions and
reservations. The results can be used as a baseline for progressive MUNE studies and any
change in MUNE of greater than 5% should not be considered as a variation in measurement.
This is contrary to a recent report indicating that the statistical MUNE cannot be used to detect
mild to moderate motor unit loss. (Blok et al., 2010).
During the course of the study, a significant fall in motor unit number was detected in 5 of the
SOD1 mutation carriers, several months before the onset of weakness and the diagnosis of
motor neurone disease (MND) being made. There was no detectable loss of motor units in the
other 15 SOD1 mutation carriers or in the group of SOD1 mutation negative relatives. From
the study, a threshold MUNE of less than 100 was considered to imply that symptoms were
imminent.
In individual cases, there was a reduction of 68% 8 months prior, 51% 4 months prior, 46% 6
months prior, 35% 10 months prior and 28% 6 months prior to the onset of weakness. Further
motor unit loss occurred as weakness progressed and the diagnosis of MND being made.
We followed 3 subjects with a family history of ALS, 2 of which had a documented SOD 1
point mutation, who were commenced on Riluzole therapy when loss of motor units were
detected using motor unit number estimation (MUNE), before the onset of symptoms i.e. pre-
symptomatic phase. A reduction in sequential MUNE was shown to improve with a thera‐
peutic intervention, Riluzole. Currently, the only effective approved treatment for MND is
Riluzole, which has a neuroprotective role, possibly due to pre-synaptic inhibition of glutamate
release. Riluzole is an anti-glutamate agent that has been approved for the treatment of patients
with amyotrophic lateral sclerosis in most countries. Treatment of human ALS patients or
transgenic Cu, Zn superoxide dimutase 1 (SOD 1) mice, most commonly produce a modest
but significant increase in survival. (Bensimon et al., 1994). There have been a least three large
randomised trials involving hundreds of patients that have been unable to show that Riluzole
is a disease altering agent nor does it have any restorative reports. (Miller et al., 2007).
Cases 1 and 2 are SOD 1 positive mutation carriers who developed non-specific symptoms of
muscle fasciculations with no clinical weakness, but had reductions in MUNE on sequential
testing. Needle EMG studies were “normal”, with no evidence of active or chronic denervation
in muscles sampled from bilateral distal and proximal muscles. Normal EMG was defined as
the absence of fasciculation and fibrillation potentials, normal motor unit potentials and
normal recruitment. A presumptive diagnosis of fALS was made, even though there are
reports on incomplete penetrance. In case 3, one could argue that there is no clear evidence
that she has fALS, even though she has a strong family history of ALS with an autosomal
dominant pattern of inheritance. Her episodic weakness and fasciculations improved after
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commencing Riluzole and recurred after discontinuing Riluzole. She also had an improvement
in MUNE and subsequent decline in MUNE, which are temporally associated with the
administration of Riluzole.
After commencing Riluzole, there was an improvement in symptoms and MUNE. It is
therefore possible that if treatment is commenced prior to significant motor neurone loss, the
progression of disease can be slowed down.
In case 3, MUNE dropped when treatment was ceased on two separate occasions and improved
when treatment was recommenced, with the operator being unaware of the Riluzole dose
changes.
In our series, we noted an improvement in symptoms, especially a decrease in muscle
fasciculations and an increase in MUNE number after commencing Riluzole. We suggest that
previous trials have been performed in the symptomatic phase of the disease when 70-80% of
motor units have already been lost, rather than in the pre-symptomatic phase of the disease,
when the therapeutic benefit might be possible. If “treatment” is commenced prior to signifi‐
cant motor neurone loss occurring, the progression of disease may be able to slowed down.
MUNE is believed to reduce because of remodelling of the motor units and in our study, the
compound muscle action potential amplitudes were maintained despite a reduction in MUNE.
This is because early in the disease, the rate of cell death is low. (Cheah et al., 2010). The increase
in MUNE may be either due to reinnervation of the damaged muscles or repair of poorly
functioning synapses, at the early stage of the disease, without resulting in a change in CMAP.
In one of the cases in the study, Riluzole was commenced once she developed mild weakness.
At the time, there was a slight reduction in MUNE, but conventional needle EMG examination
did not fulfil the criteria to make the diagnosis of MND. In view of her strong family history
and positive genetic testing, a presumed diagnosis of MND was made. Since commencing
Riluzole there has been no significant reduction in her EDB MUNE over the last 2 years, and
her weakness of right dorsiflexors has only progressed marginally from MRC grade 4+/5 to
4/5 power. It is possible that since “treatment” was commenced prior to the loss of a significant
number of motor neurones, this may have slowed down the progression of the disease in this
individual case. Early in the course of ALS, the rate of cell death is low as the amount of
neuronal damage caused by the mutation is small. As the amount of intracellular damage
increases, a critical threshold is reached, which overwhelms cellular homeostasis, resulting in
rapid apoptosis and cell death. The increase in MUNE numbers may be either due to reinner‐
vation of the damaged muscle or repair of poorly functioning synapses, at the early stage of
the disease, without resulting in a change in CMAP.
Maximum isometric grip strength was also obtained using the Jamar hydraulic dynamometer
with standardised (middle handle) positioning and instructions. Maximum isometric grip
strength did not reduce, even when MUNE dropped, once again supporting McComas’ theory
that patients can maintain normal muscle twitch tension until loss of about 70-80% of motor
units, before collateral reinnervation was unable to provide functional compensation.
(McComas et al., 1971). Maximum isometric grip strength using the Jamar hydraulic dyna‐
mometer also does not correlate with the number of functional motor neurones in thenar group
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of muscles as measured using the statistical method of MUNE, indicating that MUNE is a more
sensitive test than MVIC for monitoring disease progression in MND. It has also been shown
that MUNE is able to identify deterioration in functional motor units before handgrip maximal
voluntary isometric contraction (MVIC).
This confirms McComas’ observation that patients with substantial chronic denervation could
maintain normal muscle twitch tension until loss of about 70-80% of motor units occurs.
(McComas, 1971). This suggests that handgrip MVIC is not as sensitive as thenar MUNE for
monitoring disease progression, as it is unable to detect early motor neurone loss due to the
presence of compensatory mechanisms. The surviving motor neurones enlarge their territo‐
ries, through collateral sprouting (reinnervation) until late in the disease, when collateral
reinnervation is no longer able to provide full functional compensation. Thenar MUNE
however does examine all of the motor units that are involved in handgrip MVIC, as forearm
flexors and ulnar-innervated muscles are involved in the generation of handgrip MVIC. It also
confirms Felice’s study which showed that in patients with MND, changes in thenar MUNE
was the most sensitive outcome measure for following disease progression, when compared
to other quantitative tests, such as CMAP, isometric grip strength, forced vital capacity and
Medical Research Council manual muscle testing. (Felice, 1997).
This study also shows that there can be substantial loss in MUNE and still have an essentially
normal EMG with minimal signs of acute denervation or motor unit potential remodelling, as
one would expected that at a minimum, the muscles with transiently reduced MUNE numbers
should have reduced recruitment during EMG studies.
As there is no corroboration with needle EMG in the pre-symptomatic stage of the disease in
this study, this requires a paradigm shift in the traditional concept that needle EMG is the
“gold” standard for the diagnosis of ALS. McComas showed that patients with substantial
chronic denervation could maintain normal muscle twitch tension until loss of about 70-80%
of motor units, before collateral reinnervation was unable to provide functional compensation
(McComas, 1971). The function of motor neurons remains normal because the remaining motor
units incorporate more muscle fibres by collateral sprouting. This should result in larger motor
unit potentials, firing at higher rates with fewer motor units active i.e. reduced recruitment.
Traditional neurologists and neurophysiologists will find it hard to understand physiologi‐
cally how there can be substantial loss in MUNE and still have normal EMG with no signs of
acute denervation or motor unit potential remodelling.
As MUNE is a measure of the primary pathologic process of motor neurone loss and can
identify that the number of motor units are reduced, even in the presence of a non-diagnostic
needle EMG. Needle electromyography may reveal evidence of chronic reinnervation, but
provides little direct evidence to the extent of motor neurone and axonal loss. These cases
clearly indicate that loss of motor neurones is detectable in the pre-symptomatic phase, which
is detectable before significant needle EMG changes of pathology. In addition, compound
muscle action potential amplitudes were maintained, despite a significant reduction in MUNE.
Even though some may argue that a reduction in MUNE cannot be used to support the
diagnosis fALS, our previous study, suggests that once changes start to occur on conventional
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EMG studies, the window of opportunity to influence the progression of this condition has
been missed.
We would argue that previous trials have all be performed in the symptomatic phase of the
disease when 70-80% of motor units have already been lost, rather than in the pre-symptomatic
phase of the disease, when the therapeutic benefit might change, as “treatment” is commenced
prior to significant motor neurone loss occurring and therefore, the progression of disease can
be slowed down. MUNE numbers are believed to reduce because of remodelling of the motor
unit and in our study, the compound muscle action potential amplitudes (CMAP) were
retained as early in the course of the disease, the rate of cell death is low. The increase in MUNE
numbers may be either due to reinnervation of the damaged muscle or repair of poorly
functioning synapses, at the early stage of the disease, without resulting in a change in CMAP.
Therapies aimed at preserving motor neurones may be more feasible than trying to replace
lost motor neurones. A number of treatment or preventative strategies have been suggested,
such as measures to diminish SOD 1 aggregation or interactions to specifically reduce
apoptosis in motor neurones. As motor neurone loss at this stage is rapid and precipitous, any
potential treatment ideally should be given much earlier in SOD 1 mutation carriers. Larger
randomised trials are necessary to study this question in a prospective, blinded fashion.
Even though MUNE evaluations were performed in an unblinded fashion, the statistical
MUNE technique is performed with the assistance of an algorithm, which reduces operator
bias. The main author has been using this technique for over 10 years and any operator bias is
unintentional and unlikely to explain the marked differences in sequential MUNE.
Early in the course of ALS, the rate of cell death is low as the amount of neuronal damage
caused by the mutation is small. As the amount of intracellular damage increases, a critical
threshold is reached, which overwhelms cellular homeostasis, resulting in rapid apoptosis and
cell death. (Clarke, 2001). The mutant neurones appear to function normally for decades, with
weakness only occurring once apoptosis and cell death occurs due to a gradual accumulation
of damage within the cell. (Kong & Xu, 1998).
As motor neurone loss once it occurs is rapid and precipitous, any potential treatment will
need to be given early to SOD1 mutation carriers. Once the disease progresses, resulting in
functional impairment and disability, restorative treatments to replace lost motor neurones
becomes less feasible. To date there have been a number of drugs which have undergone
clinical trials in MND, for which there is no evidence of benefit. These include creatinine, high
dose vitamin E, Gabapentin and nerve growth factors such as brain derived neurotrophic
factor and insulin-like growth factor-1. If effective treatment for MND were to be developed
to arrest the process of degeneration, therapies aimed at preserving functional motor neurones
would be more feasible. This requires the ability to be able to identify individuals at risk of
developing the disease, which currently are SOD1 mutation carriers.
This longitudinal study showed that it was possible to detect loss of motor neurones in the
pre-symptomatic stage of MND in humans. This study provided further evidence that
considerable motor neurone loss occurred just before the onset of symptoms or weakness.
(Aggarwal, 2009).
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This study indicates that SOD1 mutation carriers have normal survival of motor neurones,
with as carriers had a full complement of motor neurones during the asymptomatic phase.
Significant pre-symptomatic loss of motor neurones did not occur in asymptomatic SOD1
mutation carriers. Sudden and widespread motor neurone death occurs at the time develop‐
ment of the symptomatic symptoms, rather than life-long motor neurone loss. Sudden,
catastrophic and multifocal loss of motor neurons occurs immediately prior to the onset of
symptoms and the development of MND. This suggests that there may be a biological trigger
initiating rapid cell loss, just prior to the onset of symptoms, rather than life-long motor
neurone loss. Also, if the trigger initiating motor neurone loss can be identified, it may be
possible to prevent motor neurone loss in familial ALS and develop treatments for sporadic
MND. The mutant SOD1 protein itself cannot be the trigger, as it is constantly expressed. There
may however be a gradual accumulation of a toxic product, possibly SOD1, which has changed
into a new toxic conformation or aggregate, resulting in neuronal damage. The possibility of
an individual neuron undergoing apoptosis increases as damage accumulates. This cumula‐
tive damage may be due to oxidative stress, resulting in disruption of the cellular structure
and function.
Neurofilament heavy polypeptide (NF-H) is an abundant stable cytoplasmic protein located
in neuronal cells in large axons and may be used as a cell type marker. Abnormal accumulation
of NF-H in motor neurones is associated with ALS, but it is unclear to what extent these
contribute to human disease. Analysis of blood serum markers looking for increased levels of
NF-H was not performed in this study, but would be interesting to be done in the future to the
compare levels of NF-H in the carriers.
The results of this study indicate that the risk of cell death probably remains constant through‐
out life of the neurone and that cell death occurs randomly in time and is independent of that
of any other neurone. This suggests a “one-hit” biochemical phenomenon in which the
mutation imposes an abnormal mutant steady state on the neurone and a single catastrophic
event randomly initiates cell death and apoptosis. Early in the course of MND, the rate of cell
death is low as the amount of neuronal damage caused by the mutation is small. The delay in
clinical onset was thought to reflect the gradual accumulation of damage within the neurones,
as a result of the mutation, which ultimately overwhelms cellular homeostasis leading to cell
death. The living mutant neurons function very well for years or decades but the probability
that an individual neurone undergoes apoptosis increases as damage accumulates within it.
A mutant neurone in an older patient will have accumulated a greater amount of damage and
will therefore be more likely to die than in a younger patient. Consequently, early in the course
of disease, the chance of a cell containing a sufficient amount of damage to initiate apoptosis
is small, and the rate of cell loss is correspondingly low. The mutant neurones appear to
function normally for decades, with weakness only occurring once apoptosis and cell death
occurs due to a gradual accumulation of damage within the cell. Therapies aimed at preserving
motor neurones may be more feasible than trying to replace lost motor neurones. A number
of treatment or preventative strategies arise, such as measures to diminish SOD1 aggregation
or interactions to specifically reduced apoptosis in motor neurones. As motor neurone loss at
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this stage is rapid and precipitous, any potential treatment will need to be given much earlier
in SOD1 mutation carriers.
Determining the mechanism by which mutations in the Cu/Zn superoxide dismutase (SOD1)
gene triggers the destruction of motor neurones causing MND remains unknown. At present,
the favoured hypothesis is that the mutation causes disease as a result of a toxic gain of function
by the mutant SOD1 provoking selective neurotoxicity, probably disrupting the intracellular
homeostasis of copper and/or protein aggregation. However, as the amount of intracellular
damage increases, the chance that a cell will die also increases. This cumulative damage may
be due to oxidative stress, in which an imbalance between the production of reactive oxygen
species and cellular antioxidant mechanisms results in chemical modifications of macromole‐
cules, thereby disrupting cellular structure and function. It is possible that the high metabolic
activity in motor neurones, combined with the toxic oxidative properties of the mutant SOD1,
causes massive mitochondrial vacuolation in motor neurones, resulting in degeneration,
earlier than other neurones, triggering the onset of weakness. Prominent cytoplasmic intra‐
cellular inclusions in motor neurones and within astrocytes surrounding them developed by
the onset of clinical disease and in some cases represented the first pathological sign of disease.
These aggregates increased in number as the disease progressed. This indicates that the mutant
SOD1 toxicity is mediated by damage to mitochondria in motor neurones and this damage
triggers the functional decline of motor neurones and the clinical onset of symptoms. The
absence of motor neurone death in the early stages of the disease indicates that the majority
of motor neurones could be rescued after early clinical diagnosis.
Regular follow-up of SOD1 carriers with MUNE may lead to early diagnosis, creating an
opportunity for future novel approaches and therapies aimed at preserving motor neurones
rather than replacing lost motor neurones. If the trigger initiating motor neurone loss can be
identified, it may be possible to prevent motor neurone loss in familial ALS. At this stage,
detecting the onset of motor neurone loss in asymptomatic individuals will identify those who
may benefit from early institution of an active management program to improve their quality
of life, until more effective treatment modalities become available for this devastating condi‐
tion This observation is an important contribution to the current understanding of the
pathogenesis of MND, as it shows that motor neurone disease does not seem to be the end
result of slow attrition of motor neurones. MUNE may be able to be used as a method of pre-
symptomatic testing of individuals who on genetic testing are SOD1 mutation carriers. Regular
follow-up of SOD1 carriers with MUNE may lead to early diagnosis, creating an opportunity
for future novel approaches and therapies aimed at preserving motor neurones rather than
replacing lost motor neurones.
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